Cognit's Innovation
Cognit is crafting a cross-cell, cross-species Frontier AI model in Generative Biology that simulates biological cells and enables high-resolution functional genomics through closed-loop, in-silico, gene and cell engineering, redefining the paradigms in genomics research.
Cognit's Focus
Industries Empowered by Cognit to Build on Our AI Platform
The current state of drug discovery is inefficient and expensive. It takes an average of 12 years and $2.6 billion to bring a new drug to market.
This is due in part to the fact that drug discovery is largely a trial-and-error process. Researchers must first identify a target gene, then develop a drug that can modulate that gene's expression. This process is often time-consuming and expensive, and it can be difficult to predict which drugs will be effective.
Cognit Edge
High-Resolution Genomics: We aim to advance traditional views, aspiring to achieve significant insights into genetic interactions.
Phenotype Prediction: We are developing methods to accurately predict phenotypes from genotypes, enhancing our understanding of genetic expression and its implications.
Novel Biomarker Discovery: We are identifying novel biomarkers to facilitate early diagnosis and targeted treatments.
Episomal Gene Synthesis: We are advancing episomal gene synthesis techniques to improve gene therapy outcomes.
Ex-vivo and In-vivo Design: We are pioneering ex-vivo and in-vivo design strategies to enhance precision in genetic engineering and therapeutic applications.
Targeted Therapies: We are in the process of identifying and validating therapeutic targets at the Genomic level with high accuracy.
Decoding the Genome: By illuminating previously unknown genomic regions, we hope to broaden our understanding of tumorigenesis.